# ZNF679

## Overview
ZNF679 is a gene that encodes the zinc finger protein 679, which is part of the zinc finger protein family known for their role in transcriptional regulation. These proteins typically function as transcription factors, binding to DNA and influencing the expression of various genes. Zinc finger protein 679, in particular, is characterized by its zinc finger domains, which facilitate its interaction with DNA and potentially other proteins. The gene's expression and function are of interest in the context of cancer research, as alterations in ZNF679 have been associated with changes in methylation patterns and somatic mutations in lung cancer, suggesting its potential as a biomarker and its involvement in cancer progression and response to treatment (Meira2023Prognostic; Xu2022Immunotherapy).

## Function


## Clinical Significance
ZNF679 has been identified as a gene with significant differences in methylation patterns between non-small cell lung cancer (NSCLC) patients and healthy subjects. These epigenetic alterations suggest that ZNF679 could serve as a potential biomarker for the diagnosis and management of lung cancer, particularly NSCLC (Meira2023Prognostic). In the context of immunotherapy for synchronous multiple primary lung cancer (sMPLC), somatic mutations in ZNF679 have been enriched in ground glass opacities (GGOs) from cases with a major pathologic response before the use of immune checkpoint inhibitors (ICIs). This indicates a possible role for ZNF679 mutations in influencing the efficacy of immunotherapy, although the study primarily highlights other mutations such as those in MUC19 and PCDHB5 (Xu2022Immunotherapy).

While the clinical significance of ZNF679 mutations is still under investigation, these findings underscore the potential impact of ZNF679 on lung cancer progression and treatment response. The gene's involvement in transcriptional regulation through its zinc finger domains suggests that alterations in ZNF679 could disrupt normal gene regulatory networks, potentially contributing to oncogenesis or affecting therapeutic outcomes.


## References


[1. (Meira2023Prognostic) Débora Dummer Meira, Maria Clara de Castro e Caetano, Matheus Correia Casotti, Aléxia Stefani Siqueira Zetum, André Felipe Monteiro Gonçalves, André Rodrigues Moreira, Augusto Henrique de Oliveira, Fellipe Pesente, Gabriel Mendonça Santana, Daniel de Almeida Duque, Gierleson Santos Cangussu Pereira, Giulia de Souza Cupertino de Castro, Isabele Pagani Pavan, João Pedro Sarcinelli Chagas, José Henrique Borges Bourguignon, Juliana Ribeiro de Oliveira, Karen Ruth Michio Barbosa, Lorena Souza Castro Altoé, Luana Santos Louro, Luiza Poppe Merigueti, Lyvia Neves Rebello Alves, Marlon Ramos Rosado Machado, Maria Luísa Rodrigues Oliveira Roque, Pedro Santana Prates, Sayuri Honorio de Paula Segáua, Taissa dos Santos Uchiya, Thomas Erik Santos Louro, Vinicius Eduardo Daleprane, Yasmin Moreto Guaitolini, Creuza Rachel Vicente, Raquel Silva dos Reis Trabach, Bruno Cancian de Araújo, Eldamária de Vargas Wolfgramm dos Santos, Flávia de Paula, Tiago José S. Lopes, Elizeu Fagundes de Carvalho, and Iúri Drumond Louro. Prognostic factors and markers in non-small cell lung cancer: recent progress and future challenges. Genes, 14(10):1906, October 2023. URL: http://dx.doi.org/10.3390/genes14101906, doi:10.3390/genes14101906. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/genes14101906)

[2. (Xu2022Immunotherapy) Lin Xu, Meiqi Shi, Siwei Wang, Ming Li, Wenda Yin, Jingyuan Zhang, Jun Zhu, Feng Jiang, Wenjia Xia, Ninglei Qiu, Zhi Zhang, Jianfeng Huang, Zhifei Ma, Fanchen Meng, Hongyu Zhu, Guozhang Dong, Jie Wang, and Rong Yin. Immunotherapy for bilateral multiple ground glass opacities: an exploratory study for synchronous multiple primary lung cancer. Frontiers in Immunology, October 2022. URL: http://dx.doi.org/10.3389/fimmu.2022.1009621, doi:10.3389/fimmu.2022.1009621. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2022.1009621)